Literature DB >> 14757005

[Primary HIV drug resistance in a prison population. REPRICOVA-2 Study].

Julio García-Guerrero1, Agustín Herrero, Miguel Bedia, Rosa Araújo, Juan C Castellano.   

Abstract

INTRODUCTION: Currently, there are few reports on primary human immunodeficiency virus (HIV) drug resistance in the prison population.
METHODS: This is a descriptive, one-day prevalence study to identify HIV drug-resistant mutations in chronically infected treatment-naïve prisoners. Systematic randomized sampling was performed and genotyping was done by automatic sequencing.
RESULTS: A total of 90 patients were studied. Two samples were found to have nucleoside reverse transcriptase inhibitor (NRTI)-resistant mutations, four had non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant mutations and one had protease inhibitor (PI)-resistant mutations.
CONCLUSIONS: There was a low rate of primary resistance in our series. Therefore, resistance testing is not required before prescribing initial antiretroviral therapy in these patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14757005     DOI: 10.1016/s0213-005x(04)73027-x

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  2 in total

1.  Low prevalence of antiretroviral resistance among HIV type 1-positive prisoners in the Southeast United States.

Authors:  Prema Menezes; David Rosen; David A Wohl; Nichole Kiziah; Joseph Sebastian; Joseph J Eron; Becky White
Journal:  AIDS Res Hum Retroviruses       Date:  2012-11-19       Impact factor: 2.205

2.  Prevalence of HIV-1 drug resistance mutations among Spanish prison inmates.

Authors:  J García-Guerrero; P Sáiz de la Hoya; J Portilla; A Marco; J Sánchez-Payá; S Moreno
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-11       Impact factor: 3.267

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.